Placebo + BAF312
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polymyositis
Conditions
Polymyositis
Trial Timeline
Apr 24, 2013 → Aug 5, 2016
NCT ID
NCT01801917About Placebo + BAF312
Placebo + BAF312 is a phase 2 stage product being developed by Novartis for Polymyositis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01801917. Target conditions include Polymyositis.
What happened to similar drugs?
0 of 1 similar drugs in Polymyositis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01801917 | Phase 2 | Terminated |
Competing Products
6 competing products in Polymyositis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tacrolimus | Astellas Pharma | Pre-clinical | 26 |
| BAF312 + Placebo | Novartis | Phase 2 | 27 |
| MEDI7734 + Placebo | Amgen | Phase 1 | 29 |
| Abatacept subcutaneous + Placebo | Bristol Myers Squibb | Phase 3 | 40 |
| KZR-616 | Kezar Life Sciences | Phase 2 | 25 |
| KZR-616 + Placebo | Kezar Life Sciences | Phase 2 | 25 |